Literature DB >> 16463116

Effect of antipsychotic drugs on DISC1 and dysbindin expression in mouse frontal cortex and hippocampus.

S Chiba1, R Hashimoto, S Hattori, M Yohda, B Lipska, D R Weinberger, H Kunugi.   

Abstract

Altered expression of Disrupted-In-Schizophrenia-1 (DISC1) and dysbindin (DTNBP1), susceptibility genes for schizophrenia, in schizophrenic brain has been reported; however, the possible effect of antipsychotics on the expression levels of these genes has not yet been studied. We measured the mRNA expression levels of these genes in frontal cortex and hippocampus of mice chronically treated with typical and atypical antipsychotics by a real-time quantitative RT-PCR method. We found that atypical antipsychotics, olanzapine and risperidone, in a clinically relevant dose increased DISC1 expression levels in frontal cortex, while a typical antipsychotic, haloperidol, did not. No significant effect on dysbindin expression levels was observed in either brain region. These data suggest that prior evidence of decreased expression of dysbindin in postmortem brain of schizophrenics is not likely to be a simple artifact of antemortem drug treatment. Our results also suggest a potential role of DISC1 in the therapeutic mechanisms of certain atypical antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16463116     DOI: 10.1007/s00702-005-0414-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  31 in total

1.  Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families.

Authors:  Sibylle G Schwab; Michael Knapp; Stephanie Mondabon; Joachim Hallmayer; Margitta Borrmann-Hassenbach; Margot Albus; Bernard Lerer; Marcella Rietschel; Matyas Trixler; Wolfgang Maier; Dieter B Wildenauer
Journal:  Am J Hum Genet       Date:  2002-12-09       Impact factor: 11.025

2.  Family-based association study of DTNBP1 in 6p22.3 and schizophrenia.

Authors:  J X Tang; J Zhou; J B Fan; X W Li; Y Y Shi; N F Gu; G Y Feng; Y L Xing; J G Shi; L He
Journal:  Mol Psychiatry       Date:  2003-08       Impact factor: 15.992

3.  Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain.

Authors:  M A Benson; S E Newey; E Martin-Rendon; R Hawkes; D J Blake
Journal:  J Biol Chem       Date:  2001-04-20       Impact factor: 5.157

4.  No evidence for association of the dysbindin gene [DTNBP1] with schizophrenia in an Irish population-based study.

Authors:  Derek W Morris; Kevin A McGhee; Siobhan Schwaiger; Paul Scully; John Quinn; David Meagher; John L Waddington; Michael Gill; Aiden P Corvin
Journal:  Schizophr Res       Date:  2003-04-01       Impact factor: 4.939

5.  Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia.

Authors:  R Hashimoto; R E Straub; C S Weickert; T M Hyde; J E Kleinman; D R Weinberger
Journal:  Mol Psychiatry       Date:  2004-03       Impact factor: 15.992

Review 6.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.

Authors:  P J Harrison; D R Weinberger
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

7.  Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia.

Authors:  Konrad Talbot; Wess L Eidem; Caroline L Tinsley; Matthew A Benson; Edward W Thompson; Rachel J Smith; Chang-Gyu Hahn; Steven J Siegel; John Q Trojanowski; Raquel E Gur; Derek J Blake; Steven E Arnold
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

8.  Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria.

Authors:  George Kirov; Dobril Ivanov; Nigel M Williams; Anna Preece; Ivan Nikolov; Radoi Milev; Svetlinka Koleva; Albena Dimitrova; Draga Toncheva; Michael C O'Donovan; Michael J Owen
Journal:  Biol Psychiatry       Date:  2004-05-15       Impact factor: 13.382

Review 9.  The molecular genetics of schizophrenia: new findings promise new insights.

Authors:  M J Owen; N M Williams; M C O'Donovan
Journal:  Mol Psychiatry       Date:  2004-01       Impact factor: 15.992

10.  Identification of a high-risk haplotype for the dystrobrevin binding protein 1 (DTNBP1) gene in the Irish study of high-density schizophrenia families.

Authors:  E J C G van den Oord; P F Sullivan; Y Jiang; D Walsh; F A O'Neill; K S Kendler; B P Riley
Journal:  Mol Psychiatry       Date:  2003-05       Impact factor: 15.992

View more
  22 in total

Review 1.  Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.

Authors:  Andrea de Bartolomeis; Gianmarco Latte; Carmine Tomasetti; Felice Iasevoli
Journal:  Mol Neurobiol       Date:  2013-09-03       Impact factor: 5.590

2.  Increased density of DISC1-immunoreactive oligodendroglial cells in fronto-parietal white matter of patients with paranoid schizophrenia.

Authors:  Hans-Gert Bernstein; Esther Jauch; Henrik Dobrowolny; Christian Mawrin; Johann Steiner; Bernhard Bogerts
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-28       Impact factor: 5.270

Review 3.  Genes and schizophrenia: beyond schizophrenia: the role of DISC1 in major mental illness.

Authors:  William Hennah; Pippa Thomson; Leena Peltonen; David Porteous
Journal:  Schizophr Bull       Date:  2006-05-12       Impact factor: 9.306

Review 4.  Schizophrenia in translation: disrupted in schizophrenia (DISC1): integrating clinical and basic findings.

Authors:  Rosalinda C Roberts
Journal:  Schizophr Bull       Date:  2006-11-30       Impact factor: 9.306

Review 5.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

6.  Dysbindin regulates the transcriptional level of myristoylated alanine-rich protein kinase C substrate via the interaction with NF-YB in mice brain.

Authors:  Hiroaki Okuda; Ryusuke Kuwahara; Shinsuke Matsuzaki; Shingo Miyata; Natsuko Kumamoto; Tsuyoshi Hattori; Shoko Shimizu; Kohei Yamada; Keisuke Kawamoto; Ryota Hashimoto; Masatoshi Takeda; Taiichi Katayama; Masaya Tohyama
Journal:  PLoS One       Date:  2010-01-19       Impact factor: 3.240

7.  Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice.

Authors:  David Delotterie; Geoffrey Ruiz; Jacques Brocard; Annie Schweitzer; Corinne Roucard; Yann Roche; Marie-Françoise Suaud-Chagny; Karine Bressand; Annie Andrieux
Journal:  Psychopharmacology (Berl)       Date:  2009-11-21       Impact factor: 4.530

8.  No association of dysbindin with symptom factors of schizophrenia in an Irish case-control sample.

Authors:  Sarah E Bergen; Ayman H Fanous; Po-Hsiu Kuo; Brandon K Wormley; F Anthony O'Neill; Dermot Walsh; Brien P Riley; Kenneth S Kendler
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

9.  Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression.

Authors:  Junxia Tang; Robert P LeGros; Natalia Louneva; Lilly Yeh; Julia W Cohen; Chang-Gyu Hahn; Derek J Blake; Steven E Arnold; Konrad Talbot
Journal:  Hum Mol Genet       Date:  2009-07-19       Impact factor: 6.150

10.  Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation of schizophrenia patients.

Authors:  Cynthia Shannon Weickert; Debora A Rothmond; Thomas M Hyde; Joel E Kleinman; Richard E Straub
Journal:  Schizophr Res       Date:  2007-10-24       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.